Computational Analyses of YY1 and Its Target RKIP Reveal Their Diagnostic and Prognostic Roles in Lung Cancer.
Yin-Yang 1 (YY1)
biomarkers
lung cancer
personalized anti-cancer therapy
raf kinase inhibitor protein (RKIP)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
12 Feb 2022
12 Feb 2022
Historique:
received:
11
11
2021
revised:
18
01
2022
accepted:
08
02
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Lung cancer (LC) represents a global threat, being the tumor with the highest mortality rate. Despite the introduction of novel therapies (e.g., targeted inhibitors, immune-checkpoint inhibitors), relapses are still very frequent. Accordingly, there is an urgent need for reliable predictive biomarkers and therapeutically druggable targets. Yin-Yang 1 (YY1) is a transcription factor that may work either as an oncogene or a tumor suppressor, depending on the genotype and the phenotype of the tumor. The Raf Kinase Inhibitory Protein (RKIP), is a tumor suppressor and immune enhancer often found downregulated in the majority of the examined cancers. In the present report, the role of both YY1 and RKIP in LC is thoroughly explored through the analysis of several deposited RNA and protein expression datasets. The computational analyses revealed that YY1 negatively regulates
Identifiants
pubmed: 35205667
pii: cancers14040922
doi: 10.3390/cancers14040922
pmc: PMC8869872
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Mol Cell Biol. 2001 Nov;21(21):7207-17
pubmed: 11585904
Crit Rev Oncog. 2011;16(3-4):211-26
pubmed: 22248055
Mol Cancer Res. 2009 Feb;7(2):221-9
pubmed: 19208738
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2411-2415
pubmed: 33093160
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Int J Mol Sci. 2020 Sep 03;21(17):
pubmed: 32899428
Int J Cancer. 2011 Jul 15;129(2):355-64
pubmed: 20878980
Drug Resist Updat. 2017 Jan;30:28-38
pubmed: 28363333
Crit Rev Oncog. 2014;19(6):455-68
pubmed: 25597355
Pathol Oncol Res. 2013 Jan;19(1):19-26
pubmed: 22692503
PLoS One. 2008 Feb 20;3(2):e1651
pubmed: 18297132
Theranostics. 2020 Mar 4;10(9):4183-4200
pubmed: 32226547
Oncogene. 2008 Apr 3;27(15):2243-8
pubmed: 17952120
Crit Rev Oncog. 2014;19(6):431-45
pubmed: 25597353
Am Soc Clin Oncol Educ Book. 2019 Jan;39:531-542
pubmed: 31099633
OMICS. 2011 May;15(5):267-72
pubmed: 21332389
Nature. 2006 Jan 19;439(7074):353-7
pubmed: 16273092
J Exp Clin Cancer Res. 2017 May 5;36(1):62
pubmed: 28476134
Exp Mol Med. 2020 Jan;52(1):41-55
pubmed: 31956270
BMC Cancer. 2011 Jun 21;11:259
pubmed: 21689459
Front Oncol. 2021 Apr 21;11:555331
pubmed: 33968710
Int J Mol Sci. 2021 Aug 06;22(16):
pubmed: 34445183
Nature. 2020 Jul;583(7818):807-812
pubmed: 32669708
Theranostics. 2020 Aug 8;10(22):10001-10015
pubmed: 32929330
Adv Anat Pathol. 2020 Jan;27(1):3-10
pubmed: 31567128
J Cancer. 2021 Mar 1;12(8):2403-2411
pubmed: 33758616
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancers (Basel). 2018 Aug 24;10(9):
pubmed: 30149591
Clin Chest Med. 2020 Mar;41(1):1-24
pubmed: 32008623
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Lung Cancer. 2013 Nov;82(2):179-89
pubmed: 24011633
Nat Commun. 2020 May 8;11(1):2285
pubmed: 32385277
N Engl J Med. 2020 Feb 6;382(6):503-513
pubmed: 31995683
PLoS One. 2010 Apr 22;5(4):e10312
pubmed: 20421987
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
J Thorac Oncol. 2019 Oct;14(10):1732-1742
pubmed: 31260833
Onco Targets Ther. 2017 Nov 23;10:5605-5619
pubmed: 29200875
Semin Respir Crit Care Med. 2020 Jun;41(3):400-408
pubmed: 32450594
Front Physiol. 2018 Nov 29;9:1710
pubmed: 30555348
Quant Biol. 2013 Jun;1(2):115-130
pubmed: 25045190
Nat Genet. 2020 Nov;52(11):1208-1218
pubmed: 33128048
Cancers (Basel). 2019 Sep 30;11(10):
pubmed: 31575023
Cancer Cell. 2020 Jan 13;37(1):21-36.e13
pubmed: 31935371
DNA Cell Biol. 2017 Nov;36(11):947-958
pubmed: 28972861
Bioinformatics. 2013 Nov 15;29(22):2892-9
pubmed: 23966112
Cell Reprogram. 2020 Dec;22(6):328-336
pubmed: 33270501
Tumour Biol. 2014 May;35(5):4377-80
pubmed: 24420151
J Hematol Oncol. 2020 May 24;13(1):58
pubmed: 32448366
Cancers (Basel). 2021 May 20;13(10):
pubmed: 34065283
Environ Toxicol. 2020 Sep 3;:
pubmed: 32881243
J Thorac Dis. 2020 Mar;12(3):1056-1069
pubmed: 32274174
Open Respir Med J. 2012;6:135-8
pubmed: 23248718
Eur Respir J. 2017 Apr 5;49(4):
pubmed: 28381431
Oncol Lett. 2017 May;13(5):3039-3045
pubmed: 28521411
Nat Med. 2018 Aug;24(8):1277-1289
pubmed: 29988129
Ann Oncol. 2019 Jul 1;30(7):1162-1169
pubmed: 30937431
Cell Mol Immunol. 2021 Feb;18(2):279-293
pubmed: 33177696
Nat Commun. 2019 Dec 12;10(1):5679
pubmed: 31831737
J Thorac Dis. 2020 Jun;12(6):3390-3398
pubmed: 32642264
Pharmaceuticals (Basel). 2020 Nov 09;13(11):
pubmed: 33182254
Front Oncol. 2019 Nov 20;9:1230
pubmed: 31824839
Lung. 2020 Dec;198(6):897-907
pubmed: 33175991
Nature. 2018 Aug;560(7718):319-324
pubmed: 30069044
Nucleic Acids Res. 2021 Jan 8;49(D1):D1046-D1057
pubmed: 33221922
Dis Model Mech. 2020 Nov 6;13(12):
pubmed: 33158935
Oncol Lett. 2016 Nov;12(5):3363-3367
pubmed: 27900005
Oncogene. 2006 Feb 23;25(8):1125-42
pubmed: 16314846
Cells. 2019 May 10;8(5):
pubmed: 31083461
J Thorac Oncol. 2019 Mar;14(3):343-357
pubmed: 30529598
Cancer Cell. 2020 Aug 10;38(2):229-246.e13
pubmed: 32707077